Currently existing immunomodulatory drugs that treat Multiple Sclerosis only work to treat relapse or attacks, manage symptoms, or modify the course of the disease.
Keep Reading →
August 8 - News
Believe it or not, 2013 is getting close to being two-thirds of the way over. Many pharmaceutical firms have enjoyed great stock returns and nice profits thus far in the year.
Keep Reading →
August 6 - News
Array Biopharma Inc (NASDAQ:ARRY), a biotech company primarily focused on discovery of drugs for cancer treatment, is making forays into the asthma market.
Keep Reading →
August 1 - News
To most people, cigarettes are often associated with lung cancer.
Keep Reading →
July 30 - News
GlaxoSmithKline plc (ADR) (NYSE:GSK) has been accused of the violation of Chinese laws wherein the company’s key officials have used around 700 agencies and firms for increasing...
Keep Reading →
July 29 - News
The study included 184 patients with mild-to-moderate persistent allergic asthma.
Keep Reading →
July 29 - News
It's been a long time since China's double-digit economic growth became the envy of nations across the world. Since then, the Chinese economy has slowed.
Keep Reading →
July 29 - News
Investors wondered for months if Sarepta Therapeutics Inc (NASDAQ:SRPT) would pursue accelerated approval for Duchenne muscular dystrophy, or DMD, drug eteplirsen.
Keep Reading →
July 25 - News
Diversification is a subject most investors understand well.
Keep Reading →
July 24 - News
The healthcare sector has been one of the best sectors for dividend hunters -- most of the companies operating in the sector generate massive cash flow and payout a large chunk...
Keep Reading →
July 24 - News
By age 35, around two-thirds of all American men will have begun to experience androgenetic alopecia, more commonly known as male pattern baldness.
Keep Reading →
July 24 - News
There's little denying that the technological, research, and medicinal aspects of patient care are improving at breakneck speed.
Keep Reading →
July 22 - News
Most recently, executives working for the U.K.-based GlaxoSmithKline plc (ADR) (NYSE:GSK) in China have been accused of, and confessed to, serious corruption and tax-related ...
Keep Reading →
July 19 - News
Early this morning, Celgene Corporation (NASDAQ:CELG) announced that it was discontinuing the phase 3 ORIGIN Trial evaluating Revlimid (lenalidomide) in B-Cell chronic lymphomatic...
Keep Reading →
July 18 - News
Over 13 million Americans have it. More than 120,000 of them die every year.
Keep Reading →
July 17 - News
With all of the factors we have to worry about in our everyday lives, it is somewhat a wonder that we're not only able to survive, but thrive, as a society.
Keep Reading →
July 15 - News
If you thought the fireworks ended after the Fourth of July celebrations last week, think again.
Keep Reading →
July 15 - News
A year ago, AVI BioPharma underwent a process from being an $85 million biotechnology company to a $1.3 billion company called Sarepta Therapeutics Inc (NASDAQ:SRPT).
Keep Reading →
July 15 - News
The Centers for Disease Control recently released a study showing that the introduction of human papillomavirus vaccines has significantly reduced infection rates among teenaged...
Keep Reading →
July 15 - News
At the American Diabetes Association meeting last month, Eli Lilly & Co. (NYSE:LLY) presented promising data for the GLP-1 agonist dulaglutide.
Keep Reading →
July 12 - News
VIVUS, Inc. (NASDAQ:VVUS) has found an Italian to help it out.
Keep Reading →
July 10 - News
At the American Diabetes Association meeting last month, Eli Lilly & Co. (NYSE:LLY) presented promising data for the GLP-1 agonist dulaglutide.
Keep Reading →
July 10 - News
"More means less." Amarin Corporation plc (ADR) (NASDAQ:AMRN) demonstrated this seemingly contradictory maxim today following its announcement of a new public offering.
Keep Reading →
July 9 - News
After more than a year, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)’ weight-loss drug Belviq has finally launched.
Keep Reading →
July 9 - News
With the SPDR S&P Biotech Index up 20% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Keep Reading →
July 8 - News
We as a country have a come a long way over the past two decades with regard to treating HIV and reducing the number of AIDS diagnoses.
Keep Reading →
July 8 - News
Investors who buy stock in the major pharmaceutical companies likely do so because of several factors, including steady growth, modest valuations, and high dividend yields.
Keep Reading →
July 5 - News
When screening for health-care dividend stocks, it's tempting to look for the ones with the highest yield.
Keep Reading →
July 5 - News
You know Belviq and Qsymia and Contrave and Empatic, but do you recall the still most widely used weight-loss drug of all? It seems almost like ancient history now, but back in...
Keep Reading →
July 3 - News
Companies know that to attract regular income-seeking investors, it helps to pay out high dividends.
Keep Reading →
July 1 - News
Famed investor Warren Buffett once called the high cost of health care a "tapeworm eating at our economic body." While he might be disgusted by the costs, it hasn't stopped ...
Keep Reading →
June 27 - Hedge Fund Analysis
Cheap generic versions of Pfizer Inc. (NYSE:PFE)'s Viagra are coming to Europe, according the generic-drug maker Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA).
Keep Reading →
June 27 - News
Let me preface this by saying that investing in the biotech sector can sometimes be nothing more than speculating.
Keep Reading →
June 27 - News
These two ratios provide an indication of how successful a company is at generating profits using shareholders' funds and debt, and they have a strong influence on dividend payments...
Keep Reading →
June 27 - News
Viagra changed the way below-the-belt jokes were told, and certainly, it empowered a lot of men in ways they couldn't have imagined. Without a doubt, Pfizer Inc.
Keep Reading →
June 25 - News
Pfizer Inc. (NYSE:PFE) was in 81 hedge funds' portfolio at the end of the first quarter of 2013. PFE shareholders have witnessed an increase in hedge fund interest recently.
Keep Reading →
June 24 - News
GlaxoSmithKline plc (ADR) (NYSE:GSK)'s long-run total return for shareholders (capital appreciation and dividends over the past 10 years) has lagged behind that of the average...
Keep Reading →
June 24 - News
LONDON -- I'm always searching for shares that can help ordinary investors like you make money from the stock market.
Keep Reading →
June 24 - News
High dividend pharmaceutical stocks have been extremely popular in recent years.
Keep Reading →
June 21 - News
Mark your calendars Amarin Corporation plc (ADR) (NASDAQ:AMRN) investors.
Keep Reading →
June 20 - News
Indeed, the shares currently yield an impressive 4.4% despite rising by more than 30% in the last three years alone.
Keep Reading →
June 20 - News
Botox may be best known for its ability to combat crow's feet and other facial wrinkles, but it also serves an important role in the medical community.
Keep Reading →
June 19 - News
Sarepta Therapeutics Inc (NASDAQ:SRPT) won't be the only stock choice for a biotech focusing on Duchenne muscular dystrophy, or DMD, much longer. Its one potential challenger...
Keep Reading →
June 18 - News
London-based pharmaceutical giant AstraZeneca plc (ADR) (NYSE:AZN) recently announced that it had agreed to purchase U.S.-based lung-drug manufacturer Pearl Therapeutics for at...
Keep Reading →
June 18 - News
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company MannKind Corporation...
Keep Reading →
June 18 - News
It may surprise you, but restless legs syndrome (RLS) affects 7% to 10% of the U.S. population, with varying degrees of severity.
Keep Reading →
June 18 - News
Recently, AstraZeneca plc (ADR) (NYSE:AZN) announced that it has agreed to acquire Pearl Therapeutics, the respiratory drug manufacturer, in a transaction worth around $1.15 billion...
Keep Reading →
June 17 - News
Investing in biotech stocks is relatively risky amid the volatility of the market. There are many factors that can greatly affect share trends and price performance.
Keep Reading →
June 13 - News
Everyone has had a friend at school who was asthmatic. Life is not easy for the chronic asthmatic.
Keep Reading →
June 12 - News